title: Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells.
abstract: BACKGROUND
  Src family kinases (SFK) collectively regulate a variety of cellular functions in many cancer types, including proliferation, invasion, motility, survival, differentiation, and angiogenesis. Although Dasatinib (BMS-354825), an ATP-competitive, small molecule tyrosine kinase inhibitor, suppresses the activity of SFKs at nanomolar concentrations, IC50 values for antiproliferative effects in glioma cell lines were well above the clinically achievable range, suggesting the need to interfere with other components of receptor-induced downstream signaling in order to achieve an optimal therapeutic effect.
  
  
  METHODS
  The cytotoxic effects of combining Src and STAT3 inhibition on glioma cell lines were evaluated using assays to measure cell proliferation, apoptosis and migration. Western blotting and immunocytochemistry was used to monitor its effects on cell signaling and morphology.
  
  
  RESULTS
  Silencing Src and STAT3 expression each partially inhibited cell proliferation and migration. In addition, JSI-124 significantly enhanced the efficacy of dasatinib in vitro. Combination of dasatinib and JSI-124 achieved significant inhibition of migration in all cell lines, which correlated with the inhibition of Src and downstream mediators of adhesion (e.g. focal adhesion kinase). Cells exposed to dasatinib and JSI-124 exhibited morphological changes that were consistent with an upstream role for Src in regulating focal adhesion complexes.
  
  
  CONCLUSIONS
  Targeting the Src and STAT pathways may contribute to the treatment of cancers that demonstrate increased levels of these signaling mediators, including malignant human glioma. Clinical studies in these tumor types are warranted.
authors.affiliation: Department of Neurosurgery, University of Pittsburgh Medical Center.
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Premkumar
authors.forename: Esther P
authors.initials: EP
authors.lastname: Jane
authors.forename: Naomi R
authors.initials: NR
authors.lastname: Agostino
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Scialabba
authors.forename: Ian F
authors.initials: IF
authors.lastname: Pollack
references.citation: J Immunol. 2008 Feb 15;180(4):2089-98
references.pmid: 18250414
references.citation: J Immunol. 2005 Oct 1;175(7):4338-46
references.pmid: 16177074
references.citation: Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32
references.pmid: 10760290
references.citation: Nat Biotechnol. 2009 Jan;27(1):77-83
references.pmid: 19098899
references.citation: Pediatr Blood Cancer. 2008 Jun;50(6):1198-206
references.pmid: 17914733
references.citation: Cancer Res. 2007 Mar 1;67(5):2226-38
references.pmid: 17332353
references.citation: Nat Rev Cancer. 2004 Jun;4(6):470-80
references.pmid: 15170449
references.citation: Oncogene. 2001 May 3;20(20):2499-513
references.pmid: 11420660
references.citation: Cancer Res. 2002 Nov 15;62(22):6659-66
references.pmid: 12438264
references.citation: Br J Cancer. 2009 Jul 7;101(1):38-47
references.pmid: 19513066
references.citation: Mol Cell Biol. 1996 Apr;16(4):1595-603
references.pmid: 8657134
references.citation: Clin Cancer Res. 2006 Mar 1;12(5):1398-401
references.pmid: 16533761
references.citation: Science. 1994 Apr 1;264(5155):95-8
references.pmid: 8140422
references.citation: Cancer Res. 2005 May 15;65(10):4153-61
references.pmid: 15899806
references.citation: Cancer Res. 2005 Oct 15;65(20):9185-9
references.pmid: 16230377
references.citation: Biochem Biophys Res Commun. 1995 May 5;210(1):74-81
references.pmid: 7741752
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32
references.pmid: 16203784
references.citation: J Cell Biol. 2002 Dec 23;159(6):923-9
references.pmid: 12486111
references.citation: Oncogene. 2002 Dec 5;21(55):8404-13
references.pmid: 12466961
references.citation: Oncogene. 2000 May 15;19(21):2474-88
references.pmid: 10851046
references.citation: Cancer Res. 2007 Mar 15;67(6):2800-8
references.pmid: 17363602
references.citation: J Thorac Oncol. 2006 Jun;1(5):403-5
references.pmid: 17409890
references.citation: Cancer Lett. 2007 Sep 18;255(1):135-44
references.pmid: 17543444
references.citation: Curr Opin Oncol. 1997 May;9(3):215-22
references.pmid: 9229142
references.citation: Oncogene. 2002 Nov 21;21(53):8075-88
references.pmid: 12444544
references.citation: Science. 1995 Jul 7;269(5220):81-3
references.pmid: 7541555
references.citation: Cancer Res. 2006 Jun 1;66(11):5542-8
references.pmid: 16740687
references.citation: Cancer Lett. 2007 Nov 8;257(1):36-46
references.pmid: 17900801
references.citation: Blood. 2006 Oct 1;108(7):2332-8
references.pmid: 16772610
references.citation: Cancer Res. 2005 Oct 15;65(20):9525-35
references.pmid: 16230418
references.citation: Clin Cancer Res. 2009 May 15;15(10):3416-22
references.pmid: 19447875
references.citation: Adv Enzyme Regul. 1984;22:27-55
references.pmid: 6382953
references.citation: Nature. 2001 Mar 29;410(6828):549-54
references.pmid: 11279485
references.citation: Nat Rev Cancer. 2006 Mar;6(3):184-92
references.pmid: 16453012
references.citation: BMC Cancer. 2003 Sep 17;3:23
references.pmid: 13678425
references.citation: Mol Cancer Ther. 2006 Dec;5(12):3014-22
references.pmid: 17148760
references.citation: Cancer Res. 2009 Mar 1;69(5):1958-65
references.pmid: 19223541
references.citation: FASEB J. 2000 Apr;14(5):729-39
references.pmid: 10744629
references.citation: Blood. 2007 Jun 15;109(12):5143-50
references.pmid: 17317857
references.citation: J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80
references.pmid: 16959960
references.citation: Br J Haematol. 2006 Oct;135(1):26-32
references.pmid: 16939498
references.citation: Nature. 1999 Feb 4;397(6718):441-6
references.pmid: 9989411
references.citation: Cancer Control. 1999 Oct;6(5):427-435
references.pmid: 10758575
references.citation: Cancer Res. 2003 Mar 15;63(6):1270-9
references.pmid: 12649187
references.citation: J Biol Chem. 2002 Nov 22;277(47):45680-7
references.pmid: 12244095
references.citation: Cancer Res. 2009 Sep 1;69(17):6889-98
references.pmid: 19690143
references.citation: Mol Carcinog. 2006 Jan;45(1):47-59
references.pmid: 16267832
references.citation: Oncogene. 2000 Dec 27;19(56):6613-26
references.pmid: 11426647
references.citation: Oncogene. 2007 Apr 12;26(17):2435-44
references.pmid: 17043651
references.citation: J Biol Chem. 2003 Jan 17;278(3):1671-9
references.pmid: 12429742
references.citation: Genes Dev. 2001 Jun 1;15(11):1311-33
references.pmid: 11390353
references.citation: Curr Opin Oncol. 1999 Nov;11(6):490-6
references.pmid: 10550013
references.citation: Mol Carcinog. 2006 May;45(5):288-301
references.pmid: 16550610
references.citation: Cell. 1994 Apr 8;77(1):63-71
references.pmid: 7512451
references.citation: J Med Chem. 2004 Dec 30;47(27):6658-61
references.pmid: 15615512
references.citation: Cancer Lett. 2009 Oct 8;283(2):143-51
references.pmid: 19398150
references.citation: Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7319-24
references.pmid: 11404481
references.citation: Breast Cancer Res Treat. 2007 Nov;105(3):319-26
references.pmid: 17268817
references.citation: Oncogene. 2002 Jan 3;21(1):65-77
references.pmid: 11791177